Is SHC a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Sotera Health (SHC) rests on Contracted volume and repeat pricing: More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. The bear case rests on the ethylene oxide tort docket is the dominant, partly quantified risk. Analysts covering it publish targets from $15.00 to $25.00 against a $15.91 share price on November 20, 2026, so even the professionals disagree by 47% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

SHC key stats

At $15.91 on November 20, 2026, Sotera Health (SHC) has a market cap of $4.5B and a P/E of 26.5 on trailing earnings (14.9 on forward earnings).

Market cap
$4.5B
P/E (trailing)
26.5
P/E (forward)
14.9
EPS (trailing 12 months)
$0.60
Price to book
6.2
Beta
1.93

Market cap, P/E and yield are measured at the $15.91 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Sotera Health (SHC)?

The last two weeks for Sotera Health, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • SHC closed at $15.91 on November 20, 2026, down 4.2% over the past five trading days (from $16.61).

Sotera Health filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to September 30, 2026 was ~$1.23 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle. Pricing and volume are the two levers the numbers turn on, and both worked through most of 2026. Second-quarter revenue rose 9.2% to $321.4 million, with Sterigenics up 8.6%, Nordion up 15.8% on the timing of cobalt-60 harvests, and Nelson Labs up 6.3% after a weak 2025. Third-quarter revenue was ~$324.9 million, up 4.4% in constant currency: Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency, while Nordion fell 12.4% on harvest timing. Adjusted EBITDA rose 4%, and adjusted EPS of $0.29, up 12%, beat the ~$0.27 consensus. Management reaffirmed full-year revenue and adjusted EBITDA guidance on a constant-currency basis (the August ranges were $1.236 billion to $1.254 billion of revenue and $634 million to $643 million of adjusted EBITDA), raised its Nelson Labs growth outlook to low-to-mid single digits, and said Sterigenics would not see its usual sequential fourth-quarter growth. It also described softness among European medical device customers that began in the middle of the third quarter and continued into the fourth, with the US relatively stable, and expects a currency headwind of more than 100 basis points in the fourth quarter. The capital structure explains much of the equity story. Sotera carried ~$2.28 billion of total debt against ~$413 million of cash at September 30, 2026, and net leverage fell to 2.9x, inside the company's 2.0x to 3.0x target range; Moody's upgraded its credit rating. A May 2026 term loan repricing cut the spread by 25 basis points and saves ~$3.5 million a year. At ~$15.83 a share on November 20, 2026 the equity is worth ~$4.52 billion, and adding ~$1.87 billion of net debt gives an enterprise value near $6.4 billion, roughly 11x trailing EBITDA. The shares jumped ~12.9% on the day of the third-quarter report but have since fallen, ending ~12.5% lower over one month, ~18.9% lower over three months and ~10.5% lower year to date, roughly flat over twelve months. JPMorgan had downgraded the stock to underweight from neutral on October 14, 2026 with a $17 price target, while RBC said in November that Sotera has a favorable setup heading into 2027. Management plans to give 2027 expectations in February 2027 and expects a meaningful capital-spending step-down, supporting a $500 million to $600 million free cash flow objective. The gap between that multiple and what infrastructure-like healthcare assets usually fetch is where the ethylene oxide tort docket sits.

The bull case: what would have to be true for $25.00

The most optimistic published target on SHC is $25.00, +57.1% from the $15.91 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Contracted volume and repeat pricing

More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. Sterigenics grew 8.3% in 2025 to $755.8 million on 4.1% pricing and 3.6% volume/mix, then added 9.1% in the first half of 2026 to $397.7 million and 8.2% in constant currency in the third quarter, with pricing at the high end of its 3-4% long-term range. Segment income margin was 54.6% for 2025 and improved another 53 basis points in the second quarter of 2026 and 57 basis points in the third. Sterilization is a required step, not a purchase decision, so the volume base moves with device production instead of with hospital capital budgets. The caveat for the fourth quarter is Europe: management saw softer demand among European device customers from mid-third quarter and does not expect Sterigenics' usual sequential fourth-quarter growth.

2. Nordion's cobalt-60 position and the harvest cycle

Nordion is the leading global supplier of cobalt-60 outside state-linked producers, and its revenue is lumpy because cobalt is harvested from nuclear reactors on a schedule, not manufactured continuously. Second-quarter 2026 revenue rose 15.8% to $49.1 million and first-half revenue rose 21.6% to $91.2 million, driven mostly by harvest timing; the same timing then cut third-quarter revenue 12.4% and segment income 11.4%, although segment margin rose 71 basis points. Segment margin was 57.3% in 2025, the highest of the three units. Cobalt-60 decays at roughly 12% a year, so customers replenish sources whether or not their own volumes grow, giving the unit a subscription-like floor. Competing production sits in Argentina, India, Russia and China, and the Russian supplier has faced export constraints in recent years.

3. Leverage coming down, and interest expense with it

Net leverage fell to 3.0x at June 30, 2026 and 2.9x at September 30, inside the 2.0x to 3.0x range management has pointed at since the IPO, and Moody's upgraded the company's rating. Interest expense, net was $69.2 million in the first half of 2026 against $81.5 million a year earlier, a $12.4 million reduction that drops straight through. In May 2026 the company repriced ~$1.42 billion of first lien term loans, cutting the spread to SOFR plus 2.25% and saving ~$3.5 million of annual interest, and full-year 2026 interest expense guidance was lowered to $135 million to $142 million in August. Operating cash flow was $111 million in the third quarter and $228 million year to date. With ethylene oxide facility upgrades due to finish in the first quarter of 2027, management expects capital spending to step down meaningfully, toward a $500 million to $600 million free cash flow objective, and lists organic growth, sterilization acquisitions, buybacks and debt paydown as uses under evaluation.

4. The sponsor register cleared out

Warburg Pincus and GTCR took Sotera public in November 2020 and held control for more than five years through a stockholders agreement carrying board designation rights. Affiliates sold 25,000,000 shares at $15.27 on March 6, 2026 and a final 31,838,253 shares at $15.168 on May 13, 2026, after which no sponsor ownership remains and the stockholders agreement terminated by its terms. Sponsor-designated directors have since left the board: Constantine Mihas of GTCR effective March 16, 2026 and James Neary of Warburg Pincus effective August 13, 2026. Alton Shader took over as chief executive from Michael Petras under an offer dated May 1, 2026. The float is now the whole company, and the queue of scheduled secondary sales that capped the stock is gone.

The bear case: what would have to be true for $15.00

The most pessimistic published target is $15.00, -5.7% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Sotera Health is worth if the risks below bite instead of the drivers above.

The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal, with an appellate decision expected in spring 2027. All Illinois cases have been assigned to one judge and pretrial proceedings are under way. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of consensus revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.28 billion against book equity of roughly $0.7 billion (price to book is ~6.2x) leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026 before recovering to 9.2% in the third quarter, when its segment margin fell 199 basis points to 32.1% on business mix, a reminder that the testing unit does not behave like the sterilization ones. Demand and sentiment are the last item. Management said European medical device customers turned less optimistic from the middle of the third quarter into the fourth, and two analysts cut fourth-quarter estimates over the 60 days to mid-November, taking consensus to ~$0.26 of EPS on ~$318 million of revenue, roughly flat year over year. After a run to the $19.85 52-week high, the stock met a JPMorgan downgrade to underweight with a $17 target in October and has since fallen below that level, closing at ~$15.83 on November 20, 2026.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SHC already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on SHC

9 analysts cover SHC, with an average target of $21.44 (+34.8% against $15.91) and a split of 8 buy, 1 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SHC forecast and price target page.

How is SHC valued?

Market cap, P/E and dividend yield at today's price are in the SHC key stats above. The business figures below come from Sotera Health's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.23 billion for the twelve months to September 30, 2026, against ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Third-quarter 2026 revenue was ~$324.9 million, up 4.4% in constant currency, after 9.2% growth in the second quarter. Full-year revenue guidance ($1.236 billion to $1.254 billion as of August) was reaffirmed on a constant-currency basis on November 3, 2026; consensus is ~$1.24 billion for 2026 and ~$1.31 billion for 2027.
  • Earnings and EPS: GAAP net income of ~$173.5 million for the twelve months to September 30, 2026, a ~14.1% net margin, against $77.9 million in fiscal 2025 and $44.4 million in fiscal 2024; trailing diluted EPS is ~$0.60. Q3 2026 net income was ~$58.4 million and adjusted EPS of $0.29, up 12%, beat the ~$0.27 consensus, the fifth straight quarter at or above estimates. Consensus adjusted EPS is ~$0.98 for 2026 and ~$1.07 for 2027.
  • Segment mix and margins: For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In Q3 2026 Sterigenics grew 8.2% and Nelson Labs 9.2% in constant currency while Nordion fell 12.4% on cobalt harvest timing; Nelson Labs' segment margin was 32.1%. Management expects full-year adjusted EBITDA margin roughly flat, near 51%.
  • Cash flow and capital spending: Operating cash flow was $111 million in Q3 2026 and $228 million year to date. Capital expenditure guidance for 2026 is $200 million to $225 million, close to 17% of revenue, so Yahoo's trailing free cash flow of ~$146 million is a small fraction of EBITDA. Management expects a meaningful capex step-down after ethylene oxide facility upgrades finish in Q1 2027, toward a $500 million to $600 million free cash flow objective.
  • Balance sheet: Total debt of ~$2.28 billion and cash of ~$413 million at September 30, 2026, for net debt near $1.87 billion and net leverage of 2.9x, inside the 2.0x to 3.0x target; Moody's upgraded the rating. The May 2026 repricing set ~$1.42 billion of term loans at SOFR plus 2.25%, and the $600 million revolver was undrawn at June 30.
  • Market pricing: The shares closed at ~$15.83 on November 20, 2026, against a 52-week range of $13.09 to $19.85, for a market capitalization of ~$4.52 billion. Enterprise value is roughly $6.4 billion, or ~11.1x trailing EBITDA on Yahoo Finance's ~$584 million basis. Trailing P/E is ~26x, forward ~15x on consensus 2027 EPS of ~$1.07, and price to trailing sales ~3.7x. Sotera pays no dividend.
  • Next report: Fourth-quarter 2026 results and 2027 expectations are due in February 2027; consensus for the December quarter is ~$0.26 of adjusted EPS on ~$317.5 million of revenue.

As of November 2026: Roughly 11x enterprise value to EBITDA is a modest price for a business earning around 51% adjusted EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation: Sotera carries no reserve for the ~970 ethylene oxide claims outstanding as of July 31, 2026, so the multiple embeds an unpriced tail, not a known cost. The ~26x trailing GAAP P/E reflects amortization, interest and settlement charges the adjusted figures strip out, and after a ~19% three-month fall and a softer European outlook the forward multiple has come down to ~15x.

How do you decide if SHC is a buy?

Whether SHC is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold SHC indirectly through an index or sector ETF before adding more.

What would change your mind on SHC

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Contracted volume and repeat pricing stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the ethylene oxide tort docket is the dominant, partly quantified risk fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the SHC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SHC against your real portfolio and see your actual exposure before deciding.

Your questions about Sotera Health

Ask Walnut's AI anything about SHC and see how it fits what you own.

FAQ

Is SHC a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Contracted volume and repeat pricing, with revenue (ttm) at ~$1.23 billion for the twelve months to September 30, 2026, against ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Third-quarter 2026 revenue was ~$324.9 million, up 4.4% in constant currency, after 9.2% growth in the second quarter. Full-year revenue guidance ($1.236 billion to $1.254 billion as of August) was reaffirmed on a constant-currency basis on November 3, 2026; consensus is ~$1.24 billion for 2026 and ~$1.31 billion for 2027.. The bear case rests on the ethylene oxide tort docket is the dominant, partly quantified risk. Analysts covering it are spread from $15.00 to $25.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell SHC?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The ethylene oxide tort docket is the dominant, partly quantified risk. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $15.00, -5.7% from the $15.91 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for SHC?

+

Contracted volume and repeat pricing. More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. The most optimistic analyst target on SHC is $25.00, +57.1% from the $15.91 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for SHC?

+

The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal, with an appellate decision expected in spring 2027. All Illinois cases have been assigned to one judge and pretrial proceedings are under way. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of consensus revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.28 billion against book equity of roughly $0.7 billion (price to book is ~6.2x) leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026 before recovering to 9.2% in the third quarter, when its segment margin fell 199 basis points to 32.1% on business mix, a reminder that the testing unit does not behave like the sterilization ones. Demand and sentiment are the last item. Management said European medical device customers turned less optimistic from the middle of the third quarter into the fourth, and two analysts cut fourth-quarter estimates over the 60 days to mid-November, taking consensus to ~$0.26 of EPS on ~$318 million of revenue, roughly flat year over year. After a run to the $19.85 52-week high, the stock met a JPMorgan downgrade to underweight with a $17 target in October and has since fallen below that level, closing at ~$15.83 on November 20, 2026. The most pessimistic published target is $15.00, -5.7% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Sotera Health do?

+

Sotera Health sterilizes medical products and runs lab testing, through Sterigenics, Nordion and Nelson Labs.

What would have to change for SHC to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Contracted volume and repeat pricing) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the ethylene oxide tort docket is the dominant, partly quantified risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Sotera Health do?

+

Sotera Health is a contract sterilization and testing provider for the medical device, pharmaceutical and food industries, operating 62 facilities in more than 50 countries with over 3,000 employees. It works through three brands. Sterigenics runs outsourced sterilization plants using gamma irradiation, ethylene oxide and electron beam. Nordion supplies cobalt-60, the radioactive source that makes gamma sterilization possible, plus the irradiator systems that hold it. Nelson Labs performs more than 900 microbiological and analytical chemistry tests and sells regulatory advisory services. Most medical products cannot be sold until they have been sterilized and validated, so the work is a required step in a customer's supply chain rather than an optional one. Over 40 of the top 50 device makers and nine of the ten largest pharmaceutical companies are customers.

Why does Sotera Health stock trade at a low multiple for its margins?

+

At ~$15.83 on November 20, 2026 Sotera trades near 11x enterprise value to trailing EBITDA, low for a business earning around a 51% adjusted EBITDA margin on largely contracted revenue. Two things account for the gap. The ethylene oxide tort docket is open, with roughly 970 personal-injury and property claims outstanding as of July 31, 2026 and no reserve taken against them, so the potential cost is unquantified, not absent; first California trials are set for January and April 2027. Second, the balance sheet still carries ~$2.28 billion of debt at 2.9x net leverage, which limits how much EBITDA reaches shareholders after $135 million to $142 million of guided 2026 interest and $200 million to $225 million of capital expenditure. In the autumn of 2026 management also flagged softer demand from European device customers.

What is the ethylene oxide litigation against Sotera Health?

+

Sterigenics and related subsidiaries have been sued by individuals alleging cancers and other injuries from low-level environmental exposure to ethylene oxide emitted from sterilization plants. The claims are individual suits, not class actions. A Cook County jury awarded $358.7 million against the company in 2022 over the former Willowbrook, Illinois facility, including $320 million in punitive damages, after which the company agreed in January 2023 to pay $408.0 million to settle over 880 Illinois claims. Further settlements followed: $35 million for 79 Atlanta claims, $30.9 million for 97 Illinois claims in April 2025 and $34.0 million for 129 more in July 2025. As of July 31, 2026 about 500 Georgia personal-injury claims, 305 Georgia property claims, 150 California claims and 15 Illinois cases remain pending. The Georgia appeal is expected to be decided in spring 2027, and the first California trials are scheduled for January and April 2027.

Walnut is informational, not investment advice, and gives no verdict on SHC. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks